Richard E. Buller, MD, PhD

Vice President and Head
Clinical Development, Oncology Business Unit
Pfizer, Inc.

Richard Buller, M.D, Ph.D was recently appointed as Head of Oncology Clinical Development at Pfizer following three years as Vice President of Translational Oncology. His former group was responsible for development of biomarker and companion diagnostic clinical strategies as well as proof of mechanism/pharmacology for drug candidates.  Recent success is reflected by the approval of crizotinib for the treatment of ALK positive NSCLC. 

Prior to joining Pfizer, Dr. Buller was Vice President of Translational Medicine at Exelixis, Inc. where his group played a central role in relating cancer drug effects in patients to drug targets and host genetics.  Prior to the Exelixis position, Dr. Buller was a Director in the Oncology Medicine Development Centre at GlaxoSmithKline (GSK) focusing on development and implementation of clinical strategies around the company’s portfolio of oncology drug candidates. At GSK, he co-led the successful sNDA  of topotecan for the treatment of cervical cancer. Previously, he was Professor, Departments of Obstetrics and Gynecology & Pharmacology, and Division Director of Gynecologic Oncology  at the University of Iowa College of Medicine for 13 years.

He is a board certified gynecologic oncologist with extensive clinical trials experience in all phases of drug development both in academia and industry. Dr. Buller has authored more than 140 publications and has received numerous awards and honors including multiple year listings in the Guide to America’s Top Physicians prepared by Consumer Research Council of America. His major laboratory research interest over the years has been the molecular genetics of ovarian cancer.